[1]徐西岳,朱新群#,刘小静.妇科恶性肿瘤患者TC方案化疗后发生重度骨髓抑制的影响因素[J].郑州大学学报(医学版),2016,(05):657-660.
 XU Xiyue,ZHU Xinqun,LIU Xiaojing.Related factors of severe bone marrow suppression of patients with gynecologic malignant tumor after chemotherapy with TC program[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2016,(05):657-660.
点击复制

妇科恶性肿瘤患者TC方案化疗后发生重度骨髓抑制的影响因素()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2016年05期
页码:
657-660
栏目:
应用研究
出版日期:
2016-08-20

文章信息/Info

Title:
Related factors of severe bone marrow suppression of patients with gynecologic malignant tumor after chemotherapy with TC program
作者:
徐西岳朱新群#刘小静
郑州大学第二附属医院妇产科 郑州 450014
Author(s):
XU Xiyue ZHU Xinqun LIU Xiaojing
Department of Gynecology and Obstetrics, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou 450014
关键词:
妇科恶性肿瘤 紫杉醇 奈达铂 化疗 重度骨髓抑制
Keywords:
gynecologic malignant tumor paclitaxel nedaplatin chemotherapy severe bone marrow suppression
分类号:
R737
摘要:
目的:研究紫杉醇+奈达铂(TC)方案化疗后3~4 d出现重度骨髓抑制的影响因素。方法:接受TC化疗的妇科恶性肿瘤患者118例,化疗后出现0、Ⅰ度骨髓抑制者58例(轻度组),Ⅱ、Ⅲ、Ⅳ度骨髓抑制者60例(重度组),采用单因素分析探讨年龄、体重指数、体表面积、有无内科并发症、肿瘤分期、化疗疗程、肿瘤类型等因素与重度骨髓抑制发生的关系,采用logistic回归分析探讨化疗后出现重度骨髓抑制的影响因素。结果:单因素分析结果表明年龄、肿瘤类型、肿瘤分期、化疗疗程与重度骨髓抑制有关(P<0.05)。Logistic回归分析表明宫颈癌、肿瘤分期、化疗疗程是重度骨髓抑制的影响因素(OR=0.046、2.357、3.121,P<0.05)。结论:肿瘤分期晚、化疗次数多是妇科恶性肿瘤患者TC方案化疗后发生重度骨髓抑制的高风险因素; 宫颈癌患者发生重度骨髓抑制的风险低于卵巢癌患者。
Abstract:
Aim: To research the related factors of severe bone marrow suppression occurred within 3-4 days after the chemotherapy with paclitaxel and nedaplatin(TC program)in patients with gynecologic malignant tumor.Methods: A total of 118 patients with gynecologic malignant tumor were treated with TC chemotherapy,among whom, 58 developed grade 0 to Ⅰ bone marrow suppression(mild group),and 60 developed grade Ⅱ or Ⅲ or Ⅳ bone marrow suppression(severe group). The relationship between related factors such as age, body mass index, body surface area, internal medicine amalgamative disease, tumor staging, chemotherapy course, tumor type and severe bone marrow suppression after chemotherapy was analyzed by single factor analysis. The influencing factors of severe bone marrow suppression were analyzed by logistic regression analysis.Results: Univariate analysis showed that age, tumor type, tumor stage, chemotherapy course were related to severe bone marrow depression(P<0.05). Logistic regression analysis showed that cervical cancer,tumor stage, and chemotherapy course were related to severe bone marrow depression(OR=0.046,2.357,3.121,P<0.05).Conclusion: Late stage of tumor, number of chemotherapy course are the risk factors for the occurrence of severe bone marrow suppression; the patients with cervical cancer have lower risk of developing severe bone marrow suppression than those with ovarian cancer.

参考文献/References:

[1] CORTÉS DE MIGUEL S,CALLEJA-HERNÁNDEZ MÁ,MENJON-BELTRÁN S,et al.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia[J].Support Care Cancer,2015,23(2):547
[2] 朱青,徐丽华.抗肿瘤药致骨髓抑制的相关因素分析[J].药学与临床研究,2015,23(1):68
[3] 谢嵩,魏长生.肿瘤化疗患者骨髓抑制发生情况调查与分析[J].中国现代应用药学,2010,27(13):1219
[4] 刘秋菊,姜玉珍,贾姣源.化疗后骨髓抑制危险因素分析[J].江西医学院学报,2005,45(3):48
[5] 王林,解海,张振东.乳腺癌术后化疗诱发重度骨髓抑制的影响因素分析[J].天津医药,2013,41(7):707
[6] 邓姗,郎景和.妇产科临床备忘录[M].北京:人民军医出版社,2003:212
[7] 谭先杰,吴鸣,郎景和.妇科恶性肿瘤化疗后骨髓抑制处理中的实用问题[J].实用妇产科杂志,2009,25(5):272
[8] 王柳春,孙慧,李凯.黄芪多糖与粒细胞集落刺激因子对化疗后骨髓功能的影响[J].中国肿瘤临床,2008,35(23):1373
[9] 张龙.乳腺癌术后化疗诱发重度骨髓抑制相关影响因素探讨[J].中外医学研究,2014,12(26):42
[10]OHNAKA H,TSUKAMOTO H,NAKAMURA T,et al.Predictors of response of patients with solid tumors to granulocyte colony-stimulating factor[J].Int J Clin Pharm,2013,35(1):45
[11]AAPRO MS,BOHLIUS J,CAMERON DA,et al.2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours[J].Eur J Cancer,2011,47(1):8
[12]余小挺,张琼,吕杰强.不同剂量重组人粒细胞集落刺激因子对晚期卵巢癌化疗后骨髓抑制继发感染的预防[J].中华医院感染学杂志,2014,24(17):4348

相似文献/References:

[1]吴诗文),张自森),刘 谦),等.二甲双胍联合化疗药物对人胃癌AGS细胞的作用*[J].郑州大学学报(医学版),2017,(01):37.[doi:10.13705/j.issn.1671-6825.2017.01.010]
 WU Shiwen),ZHANG Zisen),LIU Qian),et al.Effect of metformin combined with chemotherapeutic agents on gastric cancer cell line AGS[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2017,(05):37.[doi:10.13705/j.issn.1671-6825.2017.01.010]
[2]秦甜甜,刘卫华,张雪燕,等.Mcl-1 siRNA转染对EC9706细胞紫杉醇化疗敏感性的影响[J].郑州大学学报(医学版),2018,(03):269.[doi:10.13705/j.issn.1671-6825.2017.10.047]
 QIN Tiantian,LIU Weihua,ZHANG Xueyan,et al.Effect of Mcl-1 siRNA transfection on sensitivity of EC9706 cells to paclitaxel[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(05):269.[doi:10.13705/j.issn.1671-6825.2017.10.047]
[3]刘卫华,秦甜甜,李蕾蕾,等.Bcl-2抑制剂TW37联用紫杉醇对EC9706细胞增殖和凋亡的影响[J].郑州大学学报(医学版),2018,(04):409.[doi:10.13705/j.issn.1671-6825.2017.10.048]
 LIU Weihua,QIN Tiantian,LI Leilei,et al.Effects of Bcl-2 inhibitor TW37 combined with paclitaxel on proliferation and apoptosis of EC9706 cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(05):409.[doi:10.13705/j.issn.1671-6825.2017.10.048]
[4]惠怡然),杨珍珍),李岳衡),等.食管鳞癌紫杉醇耐药细胞株的建立及耐药机制探讨[J].郑州大学学报(医学版),2018,(05):552.[doi:10.13705/j.issn.1671-6825.2018.05.074]
 HUI Yiran),YANG Zhenzhen),LI Yueheng),et al.Establishment of esophageal squamous cell carcinoma paclitaxe-resistant cell line and investigation of its drug resistance mechanism[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(05):552.[doi:10.13705/j.issn.1671-6825.2018.05.074]

备注/Memo

备注/Memo:
#通信作者,女,1957年4月生,本科,主任医师,研究方向:妇科肿瘤、妇科内分泌,E-mail:zhuxinqun43@126.com
更新日期/Last Update: 2016-08-20